WOLVERINE Coronary Cutting Balloon
Boston Scientific Corp · Decision date Dec 1, 2025
What did the FDA decide?
FDA records P950020/S147 as a supplement to PMA P950020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 1, 2025.
FDA approval order statement
a change to the blade machining process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 1, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P950020/S147
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NWX
- Decision code
- OK30
- Decision date
- Dec 1, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.
- Applicant
- Boston Scientific Corp
- Product code
- NWX
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P950020/S147 received
Application receipt date recorded by FDA.
P950020/S147 · FDA decision
30-Day Notice
P950020/S148 · Related supplement
WOLVERINE Coronary Cutting Balloon
Timeline entries are records held by MedtechLedger for P950020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
WOLVERINE Coronary Cutting BalloonP950020/S148 | Boston Scientific Corp | PMA supplement | Jan 27, 2026 | FDA |
Explore the linked device profile
Other records with product code NWX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Scoreflex NC Scoring PTCA CatheterP200041/S005 | OrbusNeich Medical (Shenzhen) Co., Ltd. | PMA supplement | Jul 31, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S003 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S004 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S005 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Scoreflex NC Scoring PTCA CatheterP200041/S009 | OrbusNeich Medical (Shenzhen) Co., Ltd. | PMA supplement | Oct 29, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P950020/S147
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
